Véronique Debien

945 total citations · 1 hit paper
29 papers, 564 citations indexed

About

Véronique Debien is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Véronique Debien has authored 29 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Véronique Debien's work include HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Véronique Debien is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Véronique Debien collaborates with scholars based in Belgium, France and Italy. Véronique Debien's co-authors include Martine Piccart, Evandro de Azambuja, Laurence Buisseret, Alex De Caluwé, Xiaoxiao Wang, Vincent K. Tuohy, Emanuela Romano, Elisa Agostinetto, Christos Sotiriou and Philippe Aftimos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Véronique Debien

25 papers receiving 560 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy in breast cancer: an overview of current strategies and perspectives

2023 202 citations Véronique Debien, Alex De Caluwé et al. profile →

Peers

Countries citing papers authored by Véronique Debien

Since Specialization

Citations

This map shows the geographic impact of Véronique Debien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Debien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Debien more than expected).

Fields of papers citing papers by Véronique Debien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Véronique Debien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Debien. The network helps show where Véronique Debien may publish in the future.

Co-authorship network of co-authors of Véronique Debien

This figure shows the co-authorship network connecting the top 25 collaborators of Véronique Debien. A scholar is included among the top collaborators of Véronique Debien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Véronique Debien. Véronique Debien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Philippe Barthélémy, (unknown), Brieuc Sautois, Jan Van den Brande, (unknown), (unknown), Emmanuel Seront, Véronique Debien, Lieveke Ameye, Nuria Kotecki, Françoise Rothé, Sandrine Rorive, (unknown), Thibault Tricard, Thierry Roumeguère, Ahmad Awada, Nieves Martínez Chanzá	0
2	The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial 2024 ·Clinical Breast Cancer ·Véronique Debien, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Diogo Martins-Branco, Chiara Molinelli, Flavia Jacobs, Guilherme Nader Marta, (unknown), Evandro de Azambuja	6
3	The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab 2024 ·ESMO Open ·Laurence Buisseret, Yacine Barèche, David Venet, (unknown), Andrea Gombos, Patrick Emonts, Samira Majjaj, Ghizlane Rouas, (unknown), Véronique Debien, Elisa Agostinetto, Soizic Garaud, Karen Willard‐Gallo, Denis Larsimont, John Stagg, (unknown), Christos Sotiriou	4
4	84P Advancing precision oncology: Integrating immune landscape and genomics for tailored therapy in metastatic cancer patients 2024 ·Annals of Oncology ·(unknown), Véronique Debien, (unknown), (unknown), Alexandre Moreau, (unknown), (unknown), Florent Peyraud, Lucile Vanhersecke, (unknown), (unknown), Emmanuel Khalifa, (unknown), Sophie Cousin, Antoine Italiano	1
5	Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 2024 ·Critical Reviews in Oncology/Hematology ·Marianna Sirico, Flavia Jacobs, Chiara Molinelli, Guilherme Nader Marta, Véronique Debien, Hannah F. Dewhurst, Michela Palleschi, Filippo Merloni, Caterina Gianni, Ugo De Giorgi, Evandro de Azambuja	4
6	DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer 2023 ·Future Oncology ·Véronique Debien, Virginie Adam, (unknown), Elisa Agostinetto, Theodora Goulioti, Chiara Molinelli, Amal Arahmani, Gabriele Zoppoli, Martine Piccart	3
7	Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment 2023 ·Therapeutic Advances in Medical Oncology ·Guilherme Nader Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos, Evandro de Azambuja, Ahmad Awada	17
8	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges 2023 ·Journal of Clinical Medicine ·Xiaoxiao Wang, L. Collet, Mattia Rediti, Véronique Debien, Alex De Caluwé, David Venet, Emanuela Romano, Françoise Rothé, Christos Sotiriou, Laurence Buisseret	33
9	228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial 2023 ·ESMO Open ·Véronique Debien, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Chiara Molinelli, Diogo Martins-Branco, Flavia Jacobs, Guilherme Nader Marta, Matteo Lambertini, Evandro de Azambuja	0
10	Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE 2023 ·European Journal of Cancer ·S. Hescot, Véronique Debien, Julien Hadoux, D. Drui, Magalie Haissaguerre, Christelle de la Fouchardière, Delphine Vezzosi, Christine Do Cao, Rossella Libé, Christophe Le Tourneau, Éric Baudin, Christophe Massard, Pauline du Rusquec	3
11	Optimizing treatment for HER2-positive HR-positive breast cancer 2023 ·Cancer Treatment Reviews ·Véronique Debien, Evandro de Azambuja, Martine Piccart	11
12	The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study 2023 ·Breast Cancer Research and Treatment ·Diogo Martins-Branco, Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, (unknown), Sarra El-Abed, Susan Ellard, Miguel Izquierdo, (unknown), Saranya Chumsri, Martine Piccart, Alvaro Moreno‐Aspitia, (unknown), Janine Lombard, Evandro de Azambuja	0
13	Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab 2023 ·Critical Reviews in Oncology/Hematology ·Véronique Debien, Guilherme Nader Marta, Elisa Agostinetto, Marianna Sirico, Flavia Jacobs, Chiara Molinelli, Michel Moreau, Marianne Paesmans, Ugo De Giorgi, Armando Santoro, Donatienne Taylor, François P. Duhoux, Andrea Botticelli, Giacomo Barchiesi, (unknown), Matteo Lambertini, Hans Wildiers, Evandro de Azambuja, Martine Piccart	2
14	Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis 2022 ·Journal of Cancer Research and Clinical Oncology ·Diogo Martins-Branco, Guilherme Nader Marta, (unknown), Véronique Debien, Lieveke Ameye, Mariana Brandão, Kevin Punie, Angela Loizidou, Karen Willard‐Gallo, (unknown), Ahmad Awada, Martine Piccart, Evandro de Azambuja	9
15	LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) 2022 ·Annals of Oncology ·Laurence Buisseret, Delphine Loirat, (unknown), Kevin Punie, Christian Maurer, Véronique Debien, Ana Sofia Gonçalves, François Ghiringhelli, D. P. Taylor, Florian Clatot, (unknown), J-M Ferrero, Hervé Bonnefoi, J-L. Canon, François P. Duhoux, Fernando Bazán, Paulus Kristanto, Evandro de Azambuja, Michail Ignatiadis, Martine Piccart	7
16	Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study 2022 ·Critical Reviews in Oncology/Hematology ·Véronique Debien, Stéphane Vignot, Christophe Massard, Gabriel G. Malouf, Antoine Hollebecque, Jean‐Yves Scoazec, Stefan Michiels, Loïc Verlingue	7
17	Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study 2022 ·British Journal of Cancer ·Guilherme Nader Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, (unknown), (unknown), Larissa A. Korde, Yingbo Wang, Saranya Chumsri, Kathleen I. Pritchard, Michael Untch, (unknown), Daniela Dornelles Rosa, Alvaro Moreno‐Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja	1
18	Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. 2022 ·Journal of Clinical Oncology ·Nieves Martínez Chanzá, (unknown), Philippe Barthélémy, (unknown), (unknown), Jan Van den Brande, Brieuc Sautois, (unknown), Emmanuel Seront, Véronique Debien, Thierry Gil, Marianne Paesmans, Nuria Kotecki, Michail Ignatiadis, Simone Albisinni, (unknown), Thibault Tricard, (unknown), (unknown), Ahmad Awada	13
19	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer 2021 ·European Journal of Clinical Investigation ·Elisa Agostinetto, Véronique Debien, Guilherme Nader Marta, Matteo Lambertini, Martine Piccart, Evandro de Azambuja	19
20	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities 2019 ·Cancers ·Véronique Debien, (unknown), Véronique Lindner, Philippe Barthélémy, Hervé Lang, Ronan Flippot, Gabriel G. Malouf	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact